Virtual Library
Start Your Search
Cheng He
Author of
-
+
P1.09 - Pathology (Not CME Accredited Session) (ID 941)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.09-18 - 15 Cases of Clinical and Molecular Features Analysis in Pulmonary Adenoid Cystic Carcinoma (ID 11108)
16:45 - 18:00 | Author(s): Cheng He
- Abstract
Background
Pulmonary adenoid cystic carcinoma (PACC) of the lung is a malignant tumor arising in the tracheobronchial glands distributed in the airway submucosa. The aim of this study is to investigate the molecular characteristics of PACC.
a9ded1e5ce5d75814730bb4caaf49419 Method
From July 2013 to December 2016, 15 PACC patients received treatment. All the patients were diagnosed by pathology. We retrospectively reviewed the clinical data and genetic state.
4c3880bb027f159e801041b1021e88e8 Result
EGFR mutation rate was 6.67% (1/15), and it was 19del, the relationship between EGFR gene status and gender (P=1.000), age (P=1.000), smoking status (P=1.000) and stage (P=1.000) were no significant, and ALK fusion and ROS1 fusion gene was not detected.
8eea62084ca7e541d918e823422bd82e Conclusion
Gene change exists PACC, and the gene detection cannot be ignored in PACC.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.01-39 - Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress (ID 11110)
12:00 - 13:30 | Author(s): Cheng He
- Abstract
Background
As the first epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo. The phase III clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients with advanced non-small cell lung cancer (NSCLC) compared with gefitinib. The aim of this study is to investigate the acquired EGFR T790M situation of the non-small cell lung cancer patients who received icotinib treatment progress.
a9ded1e5ce5d75814730bb4caaf49419 Method
The ARMS method was used to detect the samples in 209 cases of EGFR 19del or L858R mutation non-small cell lung cancer.
4c3880bb027f159e801041b1021e88e8 Result
There were 123 cases accompanied 19del and 86 cases accompanied L858R in 209 cases non-small cell lung cancer samples who received icotinib treatment progress, the acquired T790M mutation type patients was 45.93% (96/209), icotinib treatment. resistance after the acquired T790M mutation with 19 del/L858R group had statistical difference (P<0.034).
8eea62084ca7e541d918e823422bd82e Conclusion
19 del patients who received treatment for icotinib are more likely to appear acquired T790M mutation than L858R patients from NSCLC, and we should attach importance to it.
6f8b794f3246b0c1e1780bb4d4d5dc53
